Scienture Holdings已与Summit Biosciences签署最终协议，获得抗抑郁药物Rezenopy在美国市场的独家商业化权利。此次合作将进一步加强Scienture Holdings在神经科学领域的市场布局。
根据协议条款，Scienture Holdings将负责Rezenopy在美国境内的所有商业化活动，包括市场推广、销售和分销。该交易标志着公司向精神健康治疗领域迈出重要一步。
Rezenopy作为一种新型抗抑郁药物，在临床试验中展现出良好的疗效和安全性。此次独家授权协议的达成，将为Scienture Holdings带来新的收入增长点，并扩大其产品管线。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.